1. Partridge AH, Rumble RB, Carey LA, et al. Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: Ame- rican Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2014; 32: 3307-3329.
2.
Wojciechowska U, Barańska K, Miklewska M, Didkowska JA. Cancer incidence and mortality in Poland in 2020. NOWOTWORY J Oncol 2023; 73: 129-145.
3.
Roth MY, Elmore JG, Yi-Frazier JP, Reisch LM, Oster NV, Miglioret- ti DL. Self-detection remains a key method of breast cancer detection for U.S. women. J Womens Health (Larchmt) 2011; 20: 1135-1139.
4.
Barni S, Cognetti F, Petrelli F. Is the oncotype DX test useful in elderly breast cancer patients: a subgroup analysis of real-life Ita- lian PONDx study. Breast Cancer Res Treat 2022; 191: 477-480.
5.
Syed YY. Oncotype DX Breast Recurrence Score(®): a review of its use in early-stage breast cancer. Mol Diagn Ther 2020; 24: 621-632.
6.
Skapek SX, Ferrari A, Gupta AA, et al. Rhabdomyosarcoma. Nat Rev Dis Primer 2019; 5: 1.
7.
Female breast cancer subtypes – cancer stat facts. SEER. Available from: https://seer.cancer.gov/statfacts/html/breast-subtypes.html (accessed: 05.06.2024).
8.
Fisher B, Jeong JH, Bryant J, et al Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term fin-dings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet 2004; 364: 858-868.
9.
Peto R, Davies C, Godwin J, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta- analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012; 379: 432-444.
10.
Schaafsma E, Zhang B, Schaafsma M, Tong CY, Zhang L, Cheng C. Impact of Oncotype DX testing on ER+ breast cancer treatment and survival in the first decade of use. Breast Cancer Res 2021; 23: 74.
11.
Pearce A, Haas M, Viney R, et al. Incidence and severity of self-reported chemotherapy side effects in routine care: A prospective cohort study. PLoS One 2017; 12: e0184360.
12.
Cheng R, Kong X, Wang X, Fang Y, Wang J. Oncotype DX Breast Recurrence Score Distribution and Chemotherapy Benefit among women of different age groups with HR-positive, HER2-negative, node-negative breast cancer in the SEER database. Front Oncol 2020; 10: 1583.
13.
Santa-Maria CA, Camp M, Cimino-Mathews A, Harvey S, Wright J, Stearns V. Neoadjuvant therapy for early-stage breast cancer: current practice, controversies, and future directions. Oncology (Williston Park) 2015; 29: 828-838.
14.
Excellence. NIfHaC. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer. Available from: https: //www.nice.org.uk: National Institute for Health and Care Excellence (accessed: 10.06.2024).
15.
Network. NCC. NCCN clinical practice guidelines in oncology (NCCN Guidelines): breast cancer, version 3. Available from: https : //www.nccn.org: National Comprehensive Cancer Network (accessed: 10.06.2024).
16.
Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817-2826.
17.
Habel LA, Shak S, Jacobs MK, et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res 2006; 8: R25.
18.
Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med 2018; 379: 111-121.
19.
Markopoulos C, van de Velde C, Zarca D, Ozmen V, Masetti R. Clinical evidence supporting genomic tests in early breast cancer: Do all genomic tests provide the same information? Eur J Surg Oncol 2017; 43: 909-920.
20.
Fayanju OM, Park KU, Lucci A. Molecular genomic testing for breast cancer: utility for surgeons. Ann Surg Oncol 2018; 25: 512-519.
21.
Hochheiser L, Hornberger J, Turner M, Lyman GH. Multi-gene assays: effect on chemotherapy use, toxicity and cost in estrogen receptor-positive early stage breast cancer. J Comp Eff Res 2019; 8: 289-304.
22.
Varga Z, Sinn P, Seidman AD. Summary of head-to-head comparisons of patient risk classifications by the 21-gene Recurrence Score® (RS) assay and other genomic assays for early breast cancer. Int J Cancer 2019; 145: 882-893.
23.
Sparano JA, Gray RJ, Makower DF, et al. Clinical outcomes in early breast cancer with a High 21-Gene Recurrence Score of 26 to 100 Assigned to adjuvant chemotherapy plus endocrine therapy: a secondary analysis of the TAILORx randomized clinical trial. JAMA Oncol 2020; 6: 367-374.
24.
Sparano JA, Gray RJ, Ravdin PM, et al. Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer. N Engl J Med 2019; 380: 2395-405.
25.
25. Kalinsky K, Barlow WE, Gralow JR, et al. 21-gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med 2021; 385: 2336-2347.
26.
Lux MP, Minartz C, Müller-Huesmann H, Sandor MF, Radeck-Knorre S, Neubauer AS. Budget impact of the Oncotype DX Breast Recurrence Score® test in patients with early primary hormone-receptor- positive, HER2-negative, node-positive breast cancer in Germany. Breast Care 2023; 19: 27-33.
27.
Bravaccini S, Mazza M, Maltoni R. No more disparities among regions in Italy: recent approval of genomic test reimbursability for early breast cancer patients in the country. Breast Cancer Res Treat 2023; 201: 1-3.
28.
Smyth L, Watson G, Walsh EM, et al. Economic impact of 21-gene recurrence score testing on early-stage breast cancer in Ireland. Breast Cancer Res Treat 2015; 153: 573-582.
29.
Plaud MG, Helk E, Ecker T, Herrmann KH. PCN254 assment and reimbursement of GENE Expression TESTS in breast cancer in Europe – a comparative policy analysis. Value in Health 2020; 23: S468.
30.
Fisher B, Jeong JH, Bryant J, et al . Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet 2004; 364: 858-868.
31.
Faragalla H, Plotkin A, Barnes P, et al. Ki67 in breast cancer assay: an ad hoc testing recommendation from the Canadian Association of Pathologists Task Force. Curr Oncol 2023; 30: 3079-3090.
32.
Inwald E, Klinkhammer-Schalke M, Hofstädter F, et al. Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat 2013; 139: 539-552.
33.
Petrelli F, Viale G, Cabiddu M, Barni S. Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients. Breast Cancer Res Treat 2015; 153: 477-491.
34.
Felts JL, Zhu J, Han B, Smith SJ, Truica CI. An analysis of Oncotype DX Recurrence Scores and clinicopathologic characteristics in invasive lobular breast cancer. Breast J 2017; 23: 677-686.
35.
Bae SJ, Ahn SG, Ji JH, et al. Application of the 21-Gene Recurrence Score in patients with early HR-positive/HER2-negative breast cancer: chemotherapy and survival rate according to clinical risk. Cancers (Basel) 2021; 13.
36.
Cognetti F, Masetti R, Fabi A, et al. PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy. NPJ Breast Cancer 2021; 7: 47.
37.
Curtit E, Vannetzel JM, Darmon JC, et al. Results of PONDx, a prospective multicenter study of the Oncotype DX® breast cancer assay: real-life utilization and decision impact in French clinical practice. Breast 2019; 44: 39-45.
38.
Chiru ED, Oseledchyk A, Schoetzau A, et al . Application of a 21-Gene Recurrence Score in a Swiss Single-Center Breast Cancer Population: a comparative analysis of treatment administration before and after TAILORx. Diagnostics (Basel) 2023; 14.
39.
Group EBCTC. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. Lancet 2012; 379: 432-444.
40.
Swain SM, Jeong JH, Geyer Jr CE, et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N En J Med 2010; 362: 2053-2065.
41.
Dowsett M, Cuzick J, Wale C, et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol 2010; 28: 1829-1834.
42.
Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006; 24: 3726-3734.
43.
Orucevic A, Heidel RE, Bell JL. Utilization and impact of 21-gene recurrence score assay for breast cancer in clinical practice across the United States: lessons learned from the 2010 to 2012 National Cancer Data Base analysis. Breast Cancer Res Treat 2016; 157: 427-435.
44.
LeVasseur N, Sun J, Fenton D, et al. Impact of the 21-Gene Recurrence Score assay on the treatment of estrogen receptor-positive, HER2-negative, breast cancer patients with 1-3 positive nodes: a prospective clinical utility study. Clin Breast Cancer 2022; 22: e74-e9.
45.
Hassan S, Younan R, Patocskai E, et al. Impact of the 21-gene recurrence score assay on treatment decisions and cost in patients with node-positive breast cancer: a multicenter study in Quebec. Oncologist 2022; 27: 822-831.
46.
Dieci MV, Guarneri V, Zustovich F, et al. Impact of 21-gene breast cancer assay on treatment decision for patients with T1-T3, N0-N1, estrogen receptor-positive/human epidermal growth receptor 2-negative breast cancer: final results of the prospective multicenter ROXANE study. Oncologist 2019; 24: 1424-1431.
47.
Davidson JA, Cromwell I, Ellard SL, et al. A prospective clinical utility and pharmacoeconomic study of the impact of the 21-gene Recurrence Score® assay in oestrogen receptor positive node negative breast cancer. Eur J Cancer 2013; 49: 2469-2475.
48.
Torres S, Trudeau M, Gandhi S, et al. Prospective evaluation of the impact of the 21-gene recurrence score assay on adjuvant treatment decisions for women with node-positive breast cancer in Ontario, Canada. Oncologist 2018; 23: 768-775.
49.
Lux MP, Minartz C, Muller-Huesmann H, et al. Budget impact of the Oncotype DX(R) test compared to other gene expression tests in patients with early breast cancer in Germany. Cancer Treat Res Commun 2022; 31: 100519.